262 related articles for article (PubMed ID: 22159748)
1. The impact of teriparatide adherence and persistence on fracture outcomes.
Yu S; Burge RT; Foster SA; Gelwicks S; Meadows ES
Osteoporos Int; 2012 Mar; 23(3):1103-13. PubMed ID: 22159748
[TBL] [Abstract][Full Text] [Related]
2. Hip and other fragility fracture incidence in real-world teriparatide-treated patients in the United States.
Burge RT; Disch DP; Gelwicks S; Zhang X; Krege JH
Osteoporos Int; 2017 Mar; 28(3):799-809. PubMed ID: 28028555
[TBL] [Abstract][Full Text] [Related]
3. Persistance and Compliance with Osteroporosis Therapies Among Women in a Commercially Insured Population in the United States.
Cheng LI; Durden E; Limone B; Radbill L; Juneau PL; Spangler L; Mirza FM; Stolshek BS
J Manag Care Spec Pharm; 2015 Sep; 21(9):824-33, 833a. PubMed ID: 26308229
[TBL] [Abstract][Full Text] [Related]
4. Association of teriparatide adherence and persistence with clinical and economic outcomes in Medicare Part D recipients: a retrospective cohort study.
Hazel-Fernandez L; Louder AM; Foster SA; Uribe CL; Burge RT
BMC Musculoskelet Disord; 2013 Jan; 14():4. PubMed ID: 23281846
[TBL] [Abstract][Full Text] [Related]
5. Association between teriparatide treatment persistence and adherence, and fracture incidence in Taiwan: analysis using the National Health Insurance Research Database.
Chan DC; Chang CH; Lim LC; Brnabic AJM; Tsauo JY; Burge R; Hsiao FY; Jin L; Gürbüz S; Yang RS
Osteoporos Int; 2016 Sep; 27(9):2855-2865. PubMed ID: 27172935
[TBL] [Abstract][Full Text] [Related]
6. Examining the Effect of Medication Adherence on Risk of Subsequent Fracture Among Women with a Fragility Fracture in the U.S. Medicare Population.
Keshishian A; Boytsov N; Burge R; Krohn K; Lombard L; Zhang X; Xie L; Baser O
J Manag Care Spec Pharm; 2017 Nov; 23(11):1178-1190. PubMed ID: 29083977
[TBL] [Abstract][Full Text] [Related]
7. Two-year persistence with teriparatide improved significantly after introduction of an educational and motivational support program.
van Maren MA; Wyers CE; Driessen JHM; Visser JV; de Vries F; van de Wijdeven K; Gevers S; Lems WF; Emmelot-Vonk MH; van den Bergh JPW
Osteoporos Int; 2019 Sep; 30(9):1837-1844. PubMed ID: 31321446
[TBL] [Abstract][Full Text] [Related]
8. Adherence and persistence with teriparatide among patients with commercial, Medicare, and Medicaid insurance.
Foster SA; Foley KA; Meadows ES; Johnston JA; Wang SS; Pohl GM; Long SR
Osteoporos Int; 2011 Feb; 22(2):551-7. PubMed ID: 20798929
[TBL] [Abstract][Full Text] [Related]
9. Effect of a patient-support program on once-daily teriparatide adherence and persistence in the Japan Fracture Observational Study (JFOS).
Sato M; Tsujimoto M; Kajimoto K; Uetake H; Shimoda H; Fujiwara S
Arch Osteoporos; 2018 Jul; 13(1):74. PubMed ID: 29978364
[TBL] [Abstract][Full Text] [Related]
10. Adherence and persistence in patients with severe osteoporosis treated with teriparatide.
Ziller V; Zimmermann SP; Kalder M; Ziller M; Seker-Pektas B; Hellmeyer L; Hadji P
Curr Med Res Opin; 2010 Mar; 26(3):675-81. PubMed ID: 20078188
[TBL] [Abstract][Full Text] [Related]
11. Differences in persistency with teriparatide in patients with osteoporosis according to gender and health care provider.
Kyvernitakis I; Kostev K; Kurth A; Albert US; Hadji P
Osteoporos Int; 2014 Dec; 25(12):2721-8. PubMed ID: 25011986
[TBL] [Abstract][Full Text] [Related]
12. Osteoporotic fractures and associated hospitalizations among patients treated with teriparatide compared to a matched cohort of patients not treated with teriparatide.
Boytsov N; Zhang X; Sugihara T; Taylor K; Swindle R
Curr Med Res Opin; 2015; 31(9):1665-75. PubMed ID: 26121328
[TBL] [Abstract][Full Text] [Related]
13. Teriparatide treatment patterns in osteoporosis and subsequent fracture events: a US claims analysis.
Bonafede MM; Shi N; Bower AG; Barron RL; Grauer A; Chandler DB
Osteoporos Int; 2015 Mar; 26(3):1203-12. PubMed ID: 25567774
[TBL] [Abstract][Full Text] [Related]
14. The Direct Assessment of Nonvertebral Fractures in Community Experience (DANCE) study: 2-year nonvertebral fragility fracture results.
Silverman S; Miller P; Sebba A; Weitz M; Wan X; Alam J; Masica D; Taylor KA; Ruff VA; Krohn K
Osteoporos Int; 2013 Aug; 24(8):2309-17. PubMed ID: 23404615
[TBL] [Abstract][Full Text] [Related]
15. Teriparatide treatment of severe osteoporosis reduces the risk of vertebral fractures compared with standard care in routine clinical practice.
Oswald AJ; Berg J; Milne G; Ralston SH
Calcif Tissue Int; 2014 Feb; 94(2):176-82. PubMed ID: 24026567
[TBL] [Abstract][Full Text] [Related]
16. The association of adherence to osteoporosis therapies with fracture, all-cause medical costs, and all-cause hospitalizations: a retrospective claims analysis of female health plan enrollees with osteoporosis.
Halpern R; Becker L; Iqbal SU; Kazis LE; Macarios D; Badamgarav E
J Manag Care Pharm; 2011; 17(1):25-39. PubMed ID: 21204588
[TBL] [Abstract][Full Text] [Related]
17. Association between teriparatide adherence and healthcare utilization and costs among hip fracture patients in the United States.
Zhao Y; Johnston SS; Smith DM; McMorrow D; Krege J; Krohn K
Bone; 2014 Mar; 60():221-6. PubMed ID: 24361596
[TBL] [Abstract][Full Text] [Related]
18. [The Importance of teriparatide in the treatment of osteoporosis].
Yamauchi M
Clin Calcium; 2016 Jun; 26(6):905-13. PubMed ID: 27230847
[TBL] [Abstract][Full Text] [Related]
19. Patients with prior vertebral or hip fractures treated with teriparatide in the Direct Assessment of Nonvertebral Fractures in Community Experience (DANCE) observational study.
Beall DP; Feldman RG; Gordon ML; Gruber BL; Lane JM; Valenzuela G; Yim D; Alam J; Krege JH; Krohn K
Osteoporos Int; 2016 Mar; 27(3):1191-1198. PubMed ID: 26556737
[TBL] [Abstract][Full Text] [Related]
20. Insufficient persistence of and adherence to osteoporosis pharmacotherapy in Japan.
Nakatoh S; Fujimori K; Tamaki J; Okimoto N; Ogawa S; Iki M
J Bone Miner Metab; 2021 May; 39(3):501-509. PubMed ID: 33403498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
